| 1 |
Kamar N, Legrand-Abravanel F, Izopet J, et al. Hepatitis E virus: what transplant physicians should know[J]. Am J Transplant, 2012, 12(9): 2281-2287.
|
| 2 |
Darstein F, Häuser F, Mittler J, et al. Hepatitis E is a rare finding in liver transplant patients with chronic elevated liver enzymes and biopsy-proven acute rejection[J]. Transplant Proc, 2020, 52(3): 926-931.
|
| 3 |
Celik F, Senkaya A, Gulsen Unal N, et al. Hepatitis E virus IgG seroprevalence in liver transplant patients: A retrospective single-center experience[J]. Hepatol Forum, 2021, 2(1)：7-11.
|
| 4 |
Abravanel F, Chapuy-Regaud S, Lhomme S, et al. Performance of anti-HEV assays for diagnosing acute hepatitis E in immunocompromised patients[J]. J Clin Virol, 2013, 58(4)：624-628.
|
| 5 |
Fischler B, Baumann U, Dezsofi A, et al. Hepatitis E in children: a position paper by the ESPGHAN Hepatology Committee[J]. J Pediatr Gastroenterol Nutr, 2016, 63(2)：288-294.
|
| 6 |
Coilly A, Haïm-Boukobza S, Roche B, et al. Posttransplantation hepatitis E: transfusion- transmitted hepatitis rising from the ashes[J]. Transplantation, 2013, 96(2)：e4-e6.
|
| 7 |
Inagaki Y, Oshiro Y, Tanaka T, et al. A nationwide survey of Hepatitis E virus infection and chronic hepatitis E in liver transplant recipients in Japan[J]. EBioMedicine, 2015, 2(11)：1607-1612.
|
| 8 |
Féray C, Pawlotsky JM, Roque-Afonso AM, et al. Should we screen blood products for hepatitis E virus RNA？[J]. Lancet, 2014, 383(9913)：218.
|
| 9 |
Schlosser B, Stein A, Neuhaus R, et al. Liver transplant from a donor with occult HEV infection induced chronic hepatitis and cirrhosis in the recipient[J]. J Hepatol, 2012, 56(2)：500-502.
|
| 10 |
Hewitt PE, Ijaz S, Brailsford SR, et al. Hepatitis E virus in blood components: a prevalence and transmission study in southeast England[J]. Lancet, 2014, 384(9956): 1766-1773.
|
| 11 |
Abi Nader E, Girard M, Leruez-Ville M, et al. Seroprevalence of hepatitis E virus infection in children after liver transplantation: a single-center experience in France[J]. Hepatol Gastroenterol, 2020, 44(2)：174-180.
|
| 12 |
De Winter BCM, Hesselink DA, Kamar N. Dosing ribavirin in hepatitis E-infected solid organ transplant recipients[J]. Pharmacol Res, 2018，130：308-315.
|
| 13 |
Kamar N, Rostaing L, Izopet J. Hepatitis E virus infection in immunosuppressed patients: natural historyand therapy[J]. Semin Liver Dis, 2013, 33(1)：62-70.
|
| 14 |
Belbézier A, Deroux A, Sarrot-Reynauld F, et al. Screening of hepatitis E in patients presenting for acute neurological disorders[J]．J Infect Public Health, 2020, 13(7)：1047-1050.
|
| 15 |
Webb GW, Dalton HR. Hepatitis E: an expanding epidemic with a range of complications. Clin Microbiol Infect[J]. 2020, 26(7)：828-832.
|
| 16 |
Abravanel F, Lhomme S, Chapuy-Regaud S, et al. Hepatitis E virus reinfections in solid-organ-transplant recipients can evolve into chronic infections[J]. J Infect Dis, 2014, 209(12)：1900-1906.
|
| 17 |
Schulz M, Choi M, Bachmann F, et al. Shear wave elastography-based liver fibrosis assessment in patients with chronic hepatitis E displays elevated liver stiffness regardless of previous antiviral therapy[J]. Quant Imaging Med Surg, 2022, 12(7)：3528-3538.
|
| 18 |
Kamar N, Abravanel F, Selves J, et al. Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation[J]. Transplantation, 2010，89(3)：353-360.
|
| 19 |
Buganza-Torio E, Doucette KE. Management of viral hepatitis in solid organ transplant recipients[J]. Infect Dis Clin North Am, 2018, 32(3)：635-650.
|
| 20 |
Mazzola A, Tran Minh M, Charlotte F, et al. Chronic hepatitis E viral infection after liver transplantation: a regressionof fibrosis after antiviral therapy[J]. Transplantation, 2017, 101(9)：2083-2087.
|
| 21 |
Kamar N, Izopet J, Tripon S, et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients[J]. N Engl J Med, 2014, 370(12)：1111-1120.
|
| 22 |
Carter M, Solsrud K, Yeddula S, et al. Hepatitis E diagnosis and management after liver, kidney, or heart transplant: a single-center experience[J]. 2022, 54(7)：1737-1741.
|
| 23 |
Debing Y, Gisa A, Dallmeier K, et al. A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients[J]. Gastroenterology, 2014, 147(5)：1008-1011.
|
| 24 |
Cheung CKM, Wong SH, Law AWH, et al. Transfusion-transmitted hepatitis E: what we know so far？[J]. World J Gastroenterol, 2022, 28(1)：47-75.
|
| 25 |
Zhang J, Zhang XF, Huang SJ, et al. Long-term efficacy of a hepatitis E vaccine[J]. N Engl J Med, 2015, 372(10)：914-922.
|
| 26 |
Wang Y, Zhou X, Debing Y, et al. Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus[J]. Gastroenterology, 2014, 146(7)：1775-1783.
|
| 27 |
Kamar N, Garrouste C, Haagsma EB, et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants[J]. Gastroenterology, 2011, 140(5)：1481-1489.
|
| 28 |
Markakis GE, Papatheodoridis GV, Cholongitas E. Epidemiology and treatment of hepatitis E in the liver transplantation setting: a literature review[J]. J Viral Hepat, 2022, 29(9)：698-718.
|